Le Lézard
Subjects: Conference, Product/Service, Trade Show

Acorda to Present Data at the 3rd Pan American Parkinson's Disease and Movement Disorders Congress

Acorda Therapeutics, Inc. (Nasdaq: ACOR) today announced that it will present new data on INBRIJA® (levodopa inhalation powder) and OFF Periods at the upcoming 3rd Pan American Parkinson's Disease and Movement Disorders Congress (MDS-PAS) taking place February 14-16, 2020 in Miami, FL.

The data include four posters that will be presented on Saturday, February 15, 2020, from 1 ? 2:30 PM ET:

Acorda will also host a Corporate Therapeutics Symposium titled, "Rethinking the Approach to Managing OFF Periods" on Saturday, February 15, 2020 from 12:15 to 1:15 PM. The symposium will feature a panel discussion on the practical considerations for the recognition of OFF periods and the role of INBRIJA. Speakers will include Peter A. LeWitt, MD, Director of the Parkinson's Disease and Movement Disorders Program at Henry Ford West Bloomfield Hospital, Fernando Pagan, MD, Director of the Movement Disorders Center at Georgetown University Hospital, and Mark Lew, MD, and Director of the Division for Movement Disorders at Keck/USC School of Medicine.

About Parkinson's and OFF Periods

Parkinson's is a progressive neurodegenerative disorder resulting from the gradual loss of certain neurons in the brain. These neurons are responsible for producing dopamine and that loss causes a range of symptoms including impaired movement, muscle stiffness and tremors. As Parkinson's progresses, people are likely to experience OFF periods, which are characterized by the return of Parkinson's symptoms, which can occur despite underlying baseline therapy. Approximately one million people in the U.S. and 1.2 million Europeans are diagnosed with Parkinson's; it is estimated that approximately 40 percent of people with Parkinson's in the U.S. experience OFF periods.

About Acorda Therapeutics

Acorda Therapeutics develops therapies to restore function and improve the lives of people with neurological disorders. INBRIJA is approved for intermittent treatment of OFF episodes in adults with Parkinson's disease treated with carbidopa/levodopa. INBRIJA is not to be used by patients who take or have taken a nonselective monoamine oxidase inhibitor such as phenelzine or tranylcypromine within the last two weeks. INBRIJA utilizes Acorda's innovative ARCUS® pulmonary delivery system, a technology platform designed to deliver medication through inhalation. Acorda also markets the branded AMPYRA® (dalfampridine) Extended Release Tablets, 10 mg.

Additional Important Safety Information for INBRIJA® (levodopa inhalation powder)

Please see the accompanying Full Prescribing Information available at www.INBRIJA.com/prescribing-information.PDF.

Forward-Looking Statement

This press release includes forward-looking statements. All statements, other than statements of historical facts, regarding management's expectations, beliefs, goals, plans or prospects should be considered forward-looking. These statements are subject to risks and uncertainties that could cause actual results to differ materially, including: we may not be able to successfully market Inbrija or any other products under development; we may need to raise additional funds to finance our operations, repay outstanding indebtedness or satisfy other obligations, and we may not be able to do so on acceptable terms or at all; risks associated with complex, regulated manufacturing processes for pharmaceuticals, which could affect whether we have sufficient commercial supply of Inbrija to meet market demand; third party payers (including governmental agencies) may not reimburse for the use of Inbrija or our other products at acceptable rates or at all and may impose restrictive prior authorization requirements that limit or block prescriptions; competition for Inbrija, Ampyra and other products we may develop and market in the future, including increasing competition and accompanying loss of revenues in the U.S. from generic versions of Ampyra (dalfampridine) following our loss of patent exclusivity; the ability to realize the benefits anticipated from acquisitions, among other reasons because acquired development programs are generally subject to all the risks inherent in the drug development process and our knowledge of the risks specifically relevant to acquired programs generally improves over time; the risk of unfavorable results from future studies of Inbrija (levodopa inhalation powder) or from our other research and development programs, or any other acquired or in-licensed programs ; the occurrence of adverse safety events with our products; the outcome (by judgment or settlement) and costs of legal, administrative or regulatory proceedings, investigations or inspections, including, without limitation, collective, representative or class action litigation; failure to protect our intellectual property, to defend against the intellectual property claims of others or to obtain third party intellectual property licenses needed for the commercialization of our products; and failure to comply with regulatory requirements could result in adverse action by regulatory agencies.

These and other risks are described in greater detail in our filings with the Securities and Exchange Commission. We may not actually achieve the goals or plans described in our forward-looking statements, and investors should not place undue reliance on these statements. Forward-looking statements made in this press release are made only as of the date hereof, and we disclaim any intent or obligation to update any forward-looking statements as a result of developments occurring after the date of this press release.

News published on 12 february 2020 at 07:05 and distributed by: